http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 16:21:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html <p>The US Food and Drug Administration has approved Utebzi (tebipenem pivoxil), an oral antibiotic developed by GSK plc (NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO), for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis in adult patients with limited or no alternative oral treatment options.</p><p>According to a press release from the companies, Utebzi is the first oral carbapenem antibiotic approved in the US. Carbapenems have previously been available only through intravenous administration. The drug is indicated for infections caused by specific susceptible pathogens, including <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterococcus faecalis</i>.</p><p>The approval is based on results from the http://www.streetinsider.com/Corporate+News/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html Wed, 17 Jun 2026 16:21:42 -0400 GSK SPRO http://www.streetinsider.com/Corporate+News/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html <p>The US Food and Drug Administration has approved Utebzi (tebipenem pivoxil), an oral antibiotic developed by GSK plc (NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO), for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis in adult patients with limited or no alternative oral treatment options.</p><p>According to a press release from the companies, Utebzi is the first oral carbapenem antibiotic approved in the US. Carbapenems have previously been available only through intravenous administration. The drug is indicated for infections caused by specific susceptible pathogens, including <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterococcus faecalis</i>.</p><p>The approval is based on results from the http://www.streetinsider.com/Corporate+News/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html Wed, 17 Jun 2026 16:21:42 -0400 GSK SPRO http://www.streetinsider.com/FDA/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html <p>The US Food and Drug Administration has approved Utebzi (tebipenem pivoxil), an oral antibiotic developed by GSK plc (NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO), for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis in adult patients with limited or no alternative oral treatment options.</p><p>According to a press release from the companies, Utebzi is the first oral carbapenem antibiotic approved in the US. Carbapenems have previously been available only through intravenous administration. The drug is indicated for infections caused by specific susceptible pathogens, including <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterococcus faecalis</i>.</p><p>The approval is based on results from the http://www.streetinsider.com/FDA/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html Wed, 17 Jun 2026 16:21:42 -0400 GSK SPRO http://www.streetinsider.com/FDA/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html <p>The US Food and Drug Administration has approved Utebzi (tebipenem pivoxil), an oral antibiotic developed by GSK plc (NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO), for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis in adult patients with limited or no alternative oral treatment options.</p><p>According to a press release from the companies, Utebzi is the first oral carbapenem antibiotic approved in the US. Carbapenems have previously been available only through intravenous administration. The drug is indicated for infections caused by specific susceptible pathogens, including <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Enterococcus faecalis</i>.</p><p>The approval is based on results from the http://www.streetinsider.com/FDA/FDA+approves+GSK+and+Spero%27s+oral+carbapenem+antibiotic+Utebzi/26660221.html Wed, 17 Jun 2026 16:21:42 -0400 GSK SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Press+Releases/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html <ul class="bwlistdisc"> <li> First and only oral carbapenem antibiotic approved in the US </li> <li> Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 </li> <li> More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 </li> </ul> <p> PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved <i>Utebzi, </i>an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment http://www.streetinsider.com/Business+Wire/Utebzi+%28tebipenem+pivoxil%29+approved+in+the+US+for+adults+with+complicated+urinary+tract+infections+%28cUTIs%29/26660209.html Wed, 17 Jun 2026 16:21:00 -0400 A.03822894 A.06822034 A.30746152 A.38925042 A.60012002 GSK GSK O.00173928 O.00496275 O.03285412 O.20026344 O.21204498 O.30518154 O.69857460 SPRO